66 results about "Cerebroside" patented technology

A recombinant fungal host cell producing recombinant glucocerebrosidase is provided. A functional recombinant glucocerebrosidase produced in recombinant fungal host cells is also provided. Methods for producing and isolating functional recombinant glucocerebrosidase from fungal hosts are also provided.

The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.

The invention relates to a medicament for nerve regeneration promotion, and particularly to a nerve regeneration promotion injection and a preparation method thereof. The nerve regeneration promotion injection is composed of the following ingredients in proportion: 280-320 micrograms of mouse nerve growth factor for injection, 19-21ml of single sialic acid four hexose ganglioside sodium injecta, 18-22ml of cerebroside-kinin injecta, 9-11ml of mecobalamine injecta and 9-11ml of dexamethasone acetate injecta. The five effective ingredients of the medicament provided by the invention are combined together and cooperative actions of multiple nutritive factors are utilized, so that the medicament has a significant curative effect on repairing of injured nerve, especially the repairing of spinal nerve injury. The medicament provided by the invention also has a protection effect on spinal cord transected injury at the early stage.

The invention discloses a method for separating cerebroside from sea cucumber by a high-speed countercurrent chromatography, which is characterized by comprising the following steps of: adding mixed solution of chloroform and methanol into sea cucumber dry powder, soaking at room temperature, and concentrating filter liquor to obtain a cerebroside crude extract; mixing petroleum ether, methanol and water, and respectively performing ultrasonic degasification on the formed stationary phase and mobile phase; dissolving the crude extract by using the mixed solvent, and filtering to obtain samplesolution; and pumping the stationary phase into a chromatographic column of the high-speed countercurrent chromatography, adjusting the rotating speed of a main machine and the flow rate of the mobile phase, pumping in the mobile phase, after two phase equilibria, pumping the sample solution into the chromatographic column through an introduction valve, continuously pumping in the mobile phase, collecting by steps, detecting by using a thin layer chromatography, merging the target object, concentrating, and freeze-drying to obtain the cerebroside. The preparation process has the advantages ofsimpleness, simple and convenient operation, high purification efficiency, short separation time, high stability, and suitability for separation of the cerebroside from various sea cucumber samples and industrial production.

A method of identifying a compound capable of correcting an impaired enzymatic activity of a mutant glucocerebrosidase molecule, the method comprising: (a) obtaining a first set of structure coordinates, the first set of structure coordinates defining a 3D structure of a glucocerebrosidase molecule capable of displaying normal enzymatic activity or a portion thereof; (b) computationally generating using the first set of structure coordinates a second set of structure coordinates, the second set of structure coordinates defining a predicted 3D structure of the mutant glucocerebrosidase molecule or a portion thereof; and (c) computationally identifying, using the second set of structure coordinates, a compound capable of interacting with the mutant glucocerebrosidase molecule in such a way as to correct the impaired enzymatic activity thereof, thereby identifying the compound capable of correcting the impaired enzymatic activity of the mutant glucocerebrosidase molecule. A glucocerebrosidase preparation comprising a population of glucocerebrosidase molecules, wherein substantially each of said glucocerebrosidase molecules: (i) has an amino acid sequence at least 95 percent homologous to an amino acid sequence set forth by SEQ ID NO: 1 or 8; (ii) is glycosylated at, or has an aspartatic acid residue at, glycosylation residue 1 of said amino acid sequence; and (iii) is independently unglycosylated at one or more glycosylation residues selected from the group consisting of glycosylation residues 2, 3 and 4 of said amino acid sequence.

The invention provides a preparation method of cerebroside compounds with a high purify. The preparation method comprises the following steps: smashing Termitomyces albuminosus, performing lixiviation in ethanol, suction filtration and concentration to obtain a crude sample of an ethanol extractum educt, distributing by a solvent, finally obtaining two pure compounds through performing positive and reverse phase silica gel chromatographic column separation and repeated high performance liquid chromatography purification on a normal butanol layer crude sample, and identifying the compounds as cerebroside compounds through spectral analysis. The compounds have new chemical structures, are respectively named as termitomycesphin G (n=16) and termitomycesphin H (n=18), and both have obvious quasi nerve growth factor activities confirmed by experiments. The preparation method is applied to preparation of medicaments for preventing neurodegenerative diseases, such as senile dementia and the like, and is in particular applied to the preparation of the medicaments for treating the neurodegenerative diseases, such as Alzheimer's disease and the like. The chemical structure is as follows.

A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and / or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes using transgenic plant root, particularly carrot cells. More particularly, the invention relates to host cells, particularly transgenic suspended carrot cells, vectors and methods for high yield expression and production of biologically active high mannose Glucocerebrosidase (GCD). The invention further provides for compositions and methods for the treatment of lysosomal storage diseases.

The invention provides a moisturizing mask and a preparation method thereof. The moisturizing mask comprises the following components, by weight: 0.01 to 1% of saccharide isomeride, 0.01%-1% of rhizobium gum, 0.01%-1% of tremella extract, 0.01%-0.2% of sodium hyaluronate, 0.01%-1% of codium tomentosum extract, 0.04%-1.5% of a skin conditioner, 0.1%-0.3% of a pH regulator, 0.06%-0.45% of a thickener and the balance being water. According to the moisturizing mask, various moisturizing active matters are mixed based on a scientific proportion; gene expression of filaggrin, loricrin, hyaluronan synthase-3 and acid sphingomyelinase in the skin can be up-regulated and the water locking capacity of the skin can be improved; meanwhile, synthesis of ceramide and cerebroside is promoted, absorptionof the skin to surrounding moisture is improved, so that the purpose of efficient moisturizing is achieved.

The invention discloses a separation and purification method for cerebroside and a ceramide type compound. The method comprises the following steps of: extracting soya bean lecithin serving as a raw material with petroleum ether with stirring and centrifuging the mixture; extracting lower-layer rough cerebroside solid with a low-polarity organic solvent; extracting the extracted insoluble substance with hot ethanol; combining the extract and concentrating and evaporating the combined extract to dryness to obtain purified rough cerebroside; separating the rough cerebroside by silica gel columnchromatography to obtain a dry substance I; and separating the dry substance by secondary silica gel column chromatography to obtain pure cerebroside and pure ceramide. The separation and purification method has the advantages of high raw material utilization ratio, simple process, low production cost, high purity of the obtained product, high yield and good industrial prospect.

The invention discloses a processing method of a salmon and relates to the field of food processing. The processing method comprises the steps of: killing a salmon, cleaning, and standing in an environment at 30-40 DEG C; then placing the salmon on cotton yarns, and processing for 80 seconds in the environment with the vacuum degree of 5MPa; then preserving for 24 hours by using salt; cleaning, and then baking to complete the processing of the salmon. According to the processing method, the salmon is processed at low temperature, a large amount of salmon cerebroside is extracted by virtue of a vacuum technology, and the salmon is finally processed through preserving and baking methods, so that the processed salmon can be cooked, air-dried and processed while keeping the integrity and quality of the salmon, and the related technological gap in the field is filled.

The invention provides application of cerebrosides in preparation of analgesic drugs. An animal experiment on pharmacology verifies that the cerebrosides are administrated through the ways such as intraperitoneal injection, gavage and skin smearing; all the three ways can improve the threshold values of a mouse to pains caused by heat and mechanical stimulation in a dose-dependent manner; the cerebrosides can remarkably relieve a neuropathic pain, an inflammatory pain and an acetic-acid-induced visceral pain. A cerebroside A or a cerebroside B can inhibit the activity of a vanilloid receptor TRPV1, so that the cerebrosides can increase an algesia threshold value and achieve the purpose of abirritation by lowering the activity of the vanilloid receptor TRPV1. According to the invention, the application of the cerebrosides serving as internal and external analgesic drugs is developed.

The invention discloses the application of cerebroside B which is extracted and prepared from termitomyces in preparing a medicine for treating ischemic brain injury. The application proves that a cerebroside compound has obvious treatment function on ischemic brain injury through pharmacology experiments, can reduce the cerebral infarction area which is caused by cerebral ischemia and relieve the cerebral edema through a blood-brain barrier, reduce the death of nerve cells, and simultaneously promote recovery of movement and cognitive functions after cerebral apoplexy, so the death rate of the cerebral apoplexy is reduced. The application develops the new medicine application of the cerebroside compound, and new therapeutic drugs are provided for treating diseases of the cerebral apoplexy.

Provided, among other things, is a delivery composition comprising: an aqueous carrier; a lipid component suspended in the carrier comprising significant amounts of type A lipid, fatty acid, and bilayer-stabilizing steroid(s), wherein type A lipid is one or more of any of phospholipid, ceramide(s) sphingomyelin(s) and glucocerebroside(s); and a bioactive agent, wherein (a) the delivery composition is packaged with a label with directions for mucosal, pulmonary or oral administration, and / or (b)(i) the viscosity of the composition is adjusted to a viscosity appropriate for spraying and / or (ii) the type A lipid comprises conjugate(s) of lipid-phase anchoring hydrophobic moieties and flexible, soluble polymers, and / or (iii) comprises a stabilizing effective amount of soluble polymers.

The invention aims to provide a preparation method of a cerebroside carnosine injection with good stability. The preparation method of a rabbit muscle extract for preparing the cerebroside carnosine injection comprises the following steps: mincing pretreated rabbit muscles into small blocks with the volume not higher than 1cm < 3 >; and uniformly mixing the obtained minced muscles with water for injection according to a ratio of 1: (1-3) (w / w), performing homogenizing, freezing the obtained muscle homogenate at a temperature not lower than-10 DEG C for 5-7 days, and performing melting at a temperature of 8-10 DEG C for 36-48 hours. According to the method, the extraction efficiency of the polypeptide in the rabbit muscle extract is remarkably improved, the risk that the rabbit muscle and the rabbit muscle extract are infected by microorganisms is effectively avoided, the freshness of the rabbit muscle extract is remarkably reduced, and the resource utilization rate of the rabbit muscle, the quality of drugs, the quality uniformity, the effectiveness and the safety are remarkably improved.

The invention relates to the production of enzymatically active recombinant human and animal lysosomal enzymes involving construction and expression of recombinant expression constructs comprising coding sequences of human or animal lysosomal enzymes in a plant expression system. The plant expression system provides for post-translational modification and processing to produce a recombinant gene product exhibiting enzymatic activity. The invention is demonstrated by working examples in which transgenic tobacco plants express recombinant expression constructs comprising human glucocerebrosidase nucleotide sequences. The invention is also demonstrated by working examples in which transfected tobacco plants express recombinant viral expression constructs comprising human alpha galactosidase nucleotide sequences. The recombinant lysosomal enzymes produced in accordance with the invention may be used for a variety of purposes, including but not limited to enzyme replacement therapy for the therapeutic treatment of human and animal lysosomal storage diseases.

A method, and associated kit, for assaying the activity of lysosomal enzymes present in dried bodily fluids and cell tissue samples, such as α-L-iduronidase, β-D-galactosidase, β-D-glucosidase, chitotriosidase, total α-D-galactosidase and α-D-galactosidase A, hexosaminidase A and B, α-D-mannosidase, β-D-mannosidase, α-L-fucosidase, N-acetyl-α-galactosaminidase, arylsulfatases, sphingomyelinase, β-galactocerebrosidase, iduronate-2-sulfatase and β-D-glucuronidase. The method includes: (a) combining with a dried bodily fluid or cell tissue sample containing at least one type of lysosomal enzyme: (1) an eluent, (2) an incubation buffer and (3) a substrate or substrates capable of reacting with the assayed lysosomal enzymes and producing their corresponding enzyme product or products, (b) allowing the dried bodily fluid or cell tissue sample to react with the eluent, incubation buffer and substrate or substrates for an adequate time and temperature, and (c) applying measuring means to the enzyme product to determine the activities of the lysosomal enzymes present.

The present invention relates to a process for purifying recombinant human Galactocerebroside β-Galactosidase dase (rhGALC) from a cell culture, wherein a fraction of said cell culture comprising rhGALC is subjected to chromatography on three distinct resins.

A method of treating Gaucher's disease in a subject in need thereof is provided. The method comprising orally administering to the subject a therapeutically effective amount of recombinant glucocerecbrosidase (GCD) comprised in plant cells, wherein said therapeutically effective amount of GCD corresponds to 1-1920 units / Kg / 14 days, thereby treating Gaucher's disease. Also provide unit dosage forms which comprise the glucocerecbrosidase (GCD) comprised in plant cells.

Disclosed are LIMP-2 peptides, LIMP-2 polypeptides, variants thereof, and pharmaceutical compositions comprising the LIMP-2 peptides, LIMP-2 polypeptides, or variants thereof. The disclosed peptides and polypeptides preferably comprise an amino acid sequence that is sufficient for providing a biological activity associated with LIMP-2, which may include binding and / or activating biological molecules such as β-glucocerebrosidase and binding viral protein 1 (VP1) of enterovirus 71 (E71) or coxsackievirus A16 (CA16). Also disclosed are methods of using the LIMP-2 peptides, LIMP-2 polypeptides, and variants thereof as therapeutics for treating diseases and disorders associated with β-glucocerebrosidase activity in subjects in need thereof.

The invention belongs to the technical fields of separation and purification of natural products, and discloses a method for extracting cerebroside from gynura procumbens. According to the method provided by the invention, the gynura procumbens is used as a raw material, and through the steps of two-phase solvent mixed extraction, column chromatography, crystallization and the like, the novel cerebroside can be quickly separated from the gynura procumbens; the product obtained by the method has high purity, natural molecules are not destroyed, and the product is suitable for large-scale production; and the obtained cerebroside has excellent anti-inflammatory activity and can be used for developing related anti-inflammatory drugs.

The invention discloses preparation, purification and content detection methods for cerebroside, which belong to the field of cerebroside preparation. The method for preparing the cerebroside comprises the step that: biological fermentation is carried out on tuber strains to obtain mycelium containing the cerebroside. In the method, the culture conditions and the culture medium composition in each step of liquid fermentation are optimized and screened, and the yield of the cerebroside is improved to the furthest degree. The invention also discloses a method for separating and purifying the cerebroside from the mycelium and detecting the content of the cerebroside. Tuber liquid is used for producing the cerebroside through fermentation. Compared with the existing cerebroside production method, the method has the advantages that the cost is low, the period is short, the operation is simple, the quality is controllable, the separation process is simple, and the like.

Disclosed are new small molecules having a pyrrolopyrimidine core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the small molecules which may be administered in methods of treating diseases or disorders associated with glucocerebrosidase activity, includin neurological diseases and disorders such as Gaucher's disease and Parkinson's disease. The small molecules may be utilized to generate activated glucocerebrosidase. The activated glucocerebrosidase thusly generated can be administered in enzyme replacement therapy and / or utilized in screening assays for new small molecules that bind to the activated glucocerebrosidase and / or modulate the activity of the activated glucocerebrosidase.

The invention relates to a new application of holothurian cerebroside and a derivatives thereof, in particular to an application of holothurian cerebroside and derivatives thereof in products for improving blood-brain barrier injury. Experiments prove that the holothurian cerebroside remarkably reduces blood-brain barrier injury caused by ischemia reperfusion and blood-brain barrier injury causedby lead acetate, the effect of the holothurian cerebroside and derivatives thereof in improvement of the blood-brain barrier is verified for the first time, and a new way is provided for treatment ofthe blood-brain barrier.

The present invention relates to a combination therapy for the treatment of immune-related disorders. More particularly, the invention relates to oral or mucosal synergistic compositions combining beta-glycolipids, preferably, β-glycosphingolipids with immunoglobulin molecules specific for at least one antigen derived from a component of the immune system, specifically an anti-CD3 antibody. The invention further provides methods kits and uses of the combined compositions of the invention for immuno-modulation and thereby for the treatment of immune-related disorders. In a preferred embodiment, anti-CD3 anti-body (OKT3) is orally administered in combination with β-glucosylceramide (also known as glycocerebroside) in an animal model of type 2 diabetes.

The present invention discloses a dry pretreatment and preparation method for improving extraction rate of cerebroside in lentinus edodes stems, and belongs to the field of food by-product processing.The method comprises the following steps: S1, pre-cooling fresh lentinus edodes stems; S2, drying the lentinus edodes stems using microwave / hot air until moisture content of the lentinus edodes stemsis less than 10%; S3, pulverizing and sieving the dried lentinus edodes stems to obtain lentinus edodes stem powder; S4, adding an extraction solution A into the lentinus edodes stem powder accordingto a material-liquid ratio A, using microwave / ultrasonic cooperative treatment, and then performing a centrifugation treatment A, pouring a supernatant A after the treatment and taking a precipitatefor a standby application; and S5, adding an extraction solution B to the precipitate according to a material-liquid ratio B, using an ultrasound treatment, then conducting a centrifugation treatmentB, taking out an obtained supernatant B after the treatment, and preparing a cerebroside-enriched sample. The established drying and extracting method for highly efficiently extracting cerebroside from lentinus edodes stems is short in time-consuming and high in extraction rate.

The present invention relates to gene therapies for lysosomal disorders. In particular, the present disclosure relates, in certain aspects, to compositions and methods for treating diseases associatedwith abnormal lysosomal function, such as Parkinson's disease (PD) and Gaucher's disease. In certain embodiments, the present disclosure provides expression constructs comprising a transfection geneencoding beta glucocerebrosidase (GBA), or a portion thereof, alone or in combination with one or more PD-associated genes. In certain embodiments, the present disclosure provides methods of treatingParkinson's disease by administering these expression constructs to a subject in need thereof.

The present invention is directed, in part, to the treatment of a subject having a neurodegenerative disorder, such as Parkinson's disease (PD), by providing glucocerebrosidase enzyme. The enzyme may be provided, e.g., through gene therapy or by administration of a glucocerebrosidase protein. Accordingly, the present invention encompasses glucocerebrosidase nucleic acids or proteins for use in the treatment of PD or other neurodegenerative disorders.

The invention discloses a method for supercritical extraction of cerebroside in sea cucumber. The method comprises the following steps of boiling the sea cucumber in boiled water, slicing, freeze-drying under the vacuum atmosphere, and crushing; feeding into an extraction kettle, starting supercritical CO2 (carbon dioxide) extraction equipment, pressurizing and heating CO2, and dynamically extracting the cerebroside in the sea cucumber in the extraction kettle in a supercritical liquid state; detecting and analyzing the collected cerebroside extract by a normal phase high performance liquid chromatography-evaporative light scattering detection method. Compared with the traditional extracting method, the method has the characteristics that the cerebroside in the sea cucumber is extracted by the supercritical CO2; the efficiency is high, the operation is quick, the extracting rate of a product is high, the purity of the product is high, any chemical reagent is not used, and the pollution is avoided; by optimizing each condition in the supercritical CO2 extraction, the optimum technology condition of the supercritical CO2 extraction is finally determined; under the optimum technology condition, the extracting rate of the cerebroside reaches 2.54%, and the purity of the obtained cerebroside reaches 11.2%.

Substituted pyrazolopyrimidines and dihydropyrazolopyrimidines and related compounds, their methods of manufacture, compositions containing these compounds, and methods of use of these compounds in treating lysosomal storage disorders such as Gaucher disease are described herein. The compounds are of general Formula (I)in which variables R1-R7 and X are described in the application.